[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-detail-334770-en":59,"doc-seo-334770-105":81},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":5,"data":60},{"doc_id":61,"user_id":62,"nickname":63,"user_avatar":64,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":66,"doc_content":67,"file_id":68,"file_url":69,"file_type":70,"file_size":71,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":72,"language":73,"language_code":74,"site_id":75,"html_lang":74,"table_of_contents":76,"faqs":77,"seo_title":78,"seo_description":66,"update_tm":79,"read_time":80,"preview_page_count":4},334770,4810365810221,"Aurora","https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","YBX1 as a prognostic biomarker and potential therapeutic target in hepatocellular carcinoma - A comprehensive investigation through bioinformatics analysis and in vitro study","Y-box binding protein 1 (YBX1) is a DNA/RNA binding protein implicated in malignant progression, yet a comprehensive pan-cancer characterization was lacking. This study used TIMER, TCGA and GEO to evaluate YBX1 expression, related tumor-infiltrating immune cells, and prognostic value via Kaplan–Meier and Cox analyses. LinkedOmics and KEGG enrichment identified YBX1-associated genes and lipid metabolism pathways, while shRNA knockdown assessed functional effects in hepatocellular carcinoma cells.","Translational Oncology 45 (2024) 101965  \nContents lists available at ScienceDirect  \nTranslational Oncology  \njournal [homepage:](homepage: www.elsevier.com/locate/tranon)[ www.elsevier.com/locate/tranon](homepage: www.elsevier.com/locate/tranon)  \n| Original Research\u003Cbr>YBX1 as a prognostic biomarker and potential therapeutic target in hepatocellular carcinoma: A comprehensive investigation through bioinformatics analysis and in vitro study\u003Cbr>Zizhen Lia, 1, Wenhua Lub, 1, Feng Yin b, Amin Huang a, *\u003Cbr>a Department of Medical Oncology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510000, China\u003Cbr>b State Key Laboratory of Oncology in Southern China, Sun Yat-Sen University Cancer Center, Guangzhou 510000, China |  |  |\n| --- | --- | --- |\n| A R T I C L E I N F O |  | A B S T R A C T |\n| Keywords: YBX1 Pan cancer\u003Cbr>Liver hepatocellular carcinoma Fatty acid metabolism |  | Backgrounds: Y-box binding protein 1 (YBX1) is a DNA/RNA binding protein known to contribute to the progression of various malignancies, however, a comprehensive pan-cancer analysis to investigate YBX1 across abroad spectrum of cancer types has not yet been conducted.\u003Cbr>Methods: We utilized the TIMER database for a comprehensive pan-cancer analysis and assessed YBX-1 expression via the TCGA and GEO databases. The relationship between YBX-1 expression and tumor-infiltrating cells was examined using TIMER and the R programming language. To evaluate the prognostic value of YBX1, we performed Kaplan-Meier plots and Cox regression analyses. Through LinkedOmics, we identified genes significantly correlated with YBX-1. The WEB-based Gene SeT AnaLysis Toolkit was used for KEGG pathway enrichment analysis. Additionally, using shRNA-mediated knockdown, we explored the potential role of YBX1 in tumor cell biology.\u003Cbr>Results: Our study identifies pronounced overexpression of YBX-1 across multiple cancer types, correlating with adverse outcomes, notably in liver hepatocellular carcinoma (LIHC). A distinct association between elevated YBX-1 expression and heightened immune cell infiltration suggests YBX-1′s potential role in reshaping the tumor microenvironment. Intriguingly, our KEGG pathway analysis indicated a tight nexus between YBX-1 expression and lipid metabolism. Moreover, the suppression of YBX-1 via shRNA revealed diminished cellular proliferation and marked reductions in crucial molecules steering the fatty acid synthesis pathway, implicating YBX-1′s potential regulatory role in lipid metabolism within LIHC.\u003Cbr>Conclusions: YBX-1 serves as a favorable prognostic indicator in various cancers, particularly in liver hepatocellular carcinoma. Targeting YBX1 in HCC offers potential therapeutic strategies. This work paves the way for fresh insights into targeted therapeutic approaches for cancers, especially benefiting liver hepatocellular carcinoma patients. |\n\nIntroduction  \nCancer is a leading cause of death and poses a significant public health problem worldwide. The World Health Organization reported in 2020 that cancer accounted for an estimated 10 million deaths globally, with a staggering 58.3 % estimated to occur in Asia [1]. Despite persistent scientific efforts to improve existing therapies and devise novel treatments, five-year survival rates for many types of cancer remain extremely low. Nowadays, targeted therapy is causing a paradigm shift in cancer treatment strategies, with these targets including  \nALK, BCL2, BCR-ABL, BRAF, CDK4/6, IDH1/2, NTRK1/2/3, PARP1/2, EGFR, ROS, MET, and others [2–4]. Lung adenocarcinoma represents the most extensively targeted tumor type with the use of targeted therapies. Regardless of whether patients are in the early or advanced stages of lung adenocarcinoma, targeted therapy holds a critical position, both as an adjuvant therapy for early to mid-stage patients and as palliative treatment for advanced cases. For instance, the FLAURA study demonstrated that Osimertinib can significantly extend the m","cbCaikMRTPwrfkPs","https://ap.wps.com/l/cbCaikMRTPwrfkPs","pdf",7570359,11,"English","en",105,"# Introduction\n## Targeted therapy landscape and prognostic needs\n# Methods and analyses\n## Pan-cancer expression and immune infiltration\n## Prognostic assessment\n## Pathway enrichment and gene correlation\n## shRNA functional validation","[{\"question\":\"What is the main research question about YBX1 in hepatocellular carcinoma?\",\"answer\":\"The study investigates whether YBX1 can serve as a prognostic biomarker and potential therapeutic target in hepatocellular carcinoma, supported by pan-cancer and functional evidence.\"},{\"question\":\"Which databases and analyses were used to evaluate YBX1?\",\"answer\":\"TIMER was used for pan-cancer analysis and immune infiltration assessment, while TCGA and GEO were used to assess YBX1 expression. Kaplan–Meier plots and Cox regression quantified prognostic value.\"},{\"question\":\"How did the study connect YBX1 to fatty acid metabolism?\",\"answer\":\"KEGG pathway enrichment and gene correlation analyses linked YBX1 expression with lipid/fatty acid metabolism, and shRNA-mediated YBX1 knockdown reduced proliferation and key molecules in the fatty acid synthesis pathway.\"}]","YBX1 as a prognostic biomarker and potential therapeutic target in hepatocellular carcinoma - A comprehensive investigation through bioinformatics analysis and in vitro study | PDF",1790008312,28,{"code":4,"msg":82,"data":83},"ok",{"site_id":75,"language":74,"slug":84,"title":65,"keywords":85,"description":66,"schema_data":86,"social_meta":140,"head_meta":142,"extra_data":144,"updated_unix":145},"ybx1-as-a-prognostic-biomarker-and-potential-therapeutic-target-in-hepatocellular-carcinoma-a-comprehensive-investigation-through-bioinformatics-analysis-and-in-vitro-study","",{"@graph":87,"@context":139},[88,102,122],{"@type":89,"itemListElement":90},"BreadcrumbList",[91,95,97,100],{"item":92,"name":93,"@type":94,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":96,"name":9,"@type":94,"position":14},"https://docshare.wps.com/document/",{"item":98,"name":40,"@type":94,"position":99},"https://docshare.wps.com/document/research-report/",3,{"item":101,"name":65,"@type":94,"position":19},"https://docshare.wps.com/document/ybx1-as-a-prognostic-biomarker-and-potential-therapeutic-target-in-hepatocellular-carcinoma-a-comprehensive-investigation-through-bioinformatics-analysis-and-in-vitro-study/334770/",{"url":101,"name":65,"@type":103,"image":104,"author":109,"headline":65,"publisher":111,"fileFormat":114,"inLanguage":74,"description":66,"dateModified":115,"datePublished":116,"encodingFormat":114,"isAccessibleForFree":117,"interactionStatistic":118},"DigitalDocument",{"url":105,"@type":106,"width":107,"height":108},"https://docshare.wps.com/thumbnails/ybx1-as-a-prognostic-biomarker-and-potential-therapeutic-target-in-hepatocellular-carcinoma-a-comprehensive-investigation-through-bioinformatics-analysis-and-in-vitro-study/334770.png","ImageObject",300,407,{"name":63,"@type":110},"Person",{"url":92,"name":112,"@type":113},"DocShare","Organization","application/pdf","2026-11-03","2026-09-21",true,{"@type":119,"interactionType":120,"userInteractionCount":52},"InteractionCounter",{"@type":121},"ViewAction",{"@type":123,"mainEntity":124},"FAQPage",[125,131,135],{"name":126,"@type":127,"acceptedAnswer":128},"What is the main research question about YBX1 in hepatocellular carcinoma?","Question",{"text":129,"@type":130},"The study investigates whether YBX1 can serve as a prognostic biomarker and potential therapeutic target in hepatocellular carcinoma, supported by pan-cancer and functional evidence.","Answer",{"name":132,"@type":127,"acceptedAnswer":133},"Which databases and analyses were used to evaluate YBX1?",{"text":134,"@type":130},"TIMER was used for pan-cancer analysis and immune infiltration assessment, while TCGA and GEO were used to assess YBX1 expression. Kaplan–Meier plots and Cox regression quantified prognostic value.",{"name":136,"@type":127,"acceptedAnswer":137},"How did the study connect YBX1 to fatty acid metabolism?",{"text":138,"@type":130},"KEGG pathway enrichment and gene correlation analyses linked YBX1 expression with lipid/fatty acid metabolism, and shRNA-mediated YBX1 knockdown reduced proliferation and key molecules in the fatty acid synthesis pathway.","https://schema.org",{"og:url":101,"og:type":141,"og:title":65,"og:site_name":112,"og:description":66},"article",{"robots":143,"canonical":101},"index,follow",{"doc_id":61,"site_id":75},1790402915]